Sanofi (SNYN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanofi (SNYN) has a cash flow conversion efficiency ratio of 0.043x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$2.96 Billion ≈ $170.35 Million USD) by net assets (MX$69.57 Billion ≈ $4.00 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sanofi (SNYN) market capitalisation for the company's overall valuation and market capitalisation.
Sanofi - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Sanofi's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sanofi Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanofi ranked by their cash flow conversion efficiency. Explore SNYN cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spotify Technology SA
NYSE:SPOT
|
0.097x |
|
Equinix Inc
NASDAQ:EQIX
|
0.074x |
|
GlaxoSmithKline plc
MX:GSKN
|
0.141x |
|
CVS Health Corp
NYSE:CVS
|
0.045x |
|
CME Group Inc
NASDAQ:CME
|
0.047x |
|
State Bank of India
NSE:SBIN
|
-0.265x |
|
HDFC Bank Limited
F:HDFA
|
N/A |
|
Adobe Systems Incorporated
NASDAQ:ADBE
|
0.218x |
Annual Cash Flow Conversion Efficiency for Sanofi (2013–2025)
The table below shows the annual cash flow conversion efficiency of Sanofi from 2013 to 2025. View latest Sanofi stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$71.71 Billion ≈ $4.13 Billion |
MX$10.75 Billion ≈ $618.67 Million |
0.150x | +28.53% |
| 2024-12-31 | MX$77.86 Billion ≈ $4.48 Billion |
MX$9.08 Billion ≈ $522.61 Million |
0.117x | -15.46% |
| 2023-12-31 | MX$74.35 Billion ≈ $4.28 Billion |
MX$10.26 Billion ≈ $590.35 Million |
0.138x | -3.65% |
| 2022-12-31 | MX$73.51 Billion ≈ $4.23 Billion |
MX$10.53 Billion ≈ $605.77 Million |
0.143x | -6.06% |
| 2021-12-31 | MX$69.03 Billion ≈ $3.97 Billion |
MX$10.52 Billion ≈ $605.54 Million |
0.152x | +29.75% |
| 2020-12-31 | MX$63.15 Billion ≈ $3.63 Billion |
MX$7.42 Billion ≈ $426.91 Million |
0.117x | -10.00% |
| 2019-12-31 | MX$59.11 Billion ≈ $3.40 Billion |
MX$7.71 Billion ≈ $444.00 Million |
0.131x | +38.91% |
| 2018-12-31 | MX$59.03 Billion ≈ $3.40 Billion |
MX$5.55 Billion ≈ $319.23 Million |
0.094x | -25.82% |
| 2017-12-31 | MX$58.26 Billion ≈ $3.35 Billion |
MX$7.38 Billion ≈ $424.66 Million |
0.127x | -6.72% |
| 2016-12-31 | MX$57.72 Billion ≈ $3.32 Billion |
MX$7.84 Billion ≈ $451.08 Million |
0.136x | -11.39% |
| 2015-12-31 | MX$58.21 Billion ≈ $3.35 Billion |
MX$8.92 Billion ≈ $513.35 Million |
0.153x | +12.12% |
| 2014-12-31 | MX$56.27 Billion ≈ $3.24 Billion |
MX$7.69 Billion ≈ $442.56 Million |
0.137x | +12.09% |
| 2013-12-31 | MX$57.03 Billion ≈ $3.28 Billion |
MX$6.95 Billion ≈ $400.20 Million |
0.122x | -- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more